Processa director buys 2,067 shares at $2.22

Processa Pharmaceuticals director and Pres.

Rhea-AI Filing Summary

Processa Pharmaceuticals director and Pres. Research & Development David Young reported an open-market purchase of common stock. He bought 2,067 shares on June 15, 2026 at $2.22 per share, bringing his directly held position to 19,198 shares of Processa Pharmaceuticals common stock.

In addition to these directly owned shares, he is also reported as having indirect ownership of 1,009 shares through CorLyst, LLC, 432 shares through Family Entities, and 1,242 shares through the Young-Plaisance Revocable Trust as of the same date.

Insider Trade Summary

Net Buyer: 2,067 shares

Net Buy 4 txns

Insider Young David

Role Pres. Research & Development

Bought 2,067 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,067	$2.22	$5K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 19,198 shares (Direct); Common Stock — 1,242 shares (Indirect, By Young-Plaisance Revocable Trust); Common Stock — 432 shares (Indirect, By Family Entities); Common Stock — 1,009 shares (Indirect, By CorLyst, LLC)

Key Figures

Shares purchased: 2,067 shares Purchase price: $2.22 per share Direct holdings after transaction: 19,198 shares +3 more

6 metrics

Shares purchased 2,067 shares Open-market purchase of common stock on June 15, 2026

Purchase price $2.22 per share Price for non-derivative open-market purchase

Direct holdings after transaction 19,198 shares Total directly owned common stock following purchase

Indirect holdings via CorLyst, LLC 1,009 shares Indirectly owned common stock

Indirect holdings via Family Entities 432 shares Indirectly owned common stock

Indirect holdings via Revocable Trust 1,242 shares Indirectly owned common stock through Young-Plaisance Revocable Trust

Key Terms

open-market purchase, indirect ownership, non-derivative, Revocable Trust

4 terms

open-market purchase financial

"transaction_action is listed as an open-market purchase of common stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

"ownership_type is indirect with nature of ownership by CorLyst, LLC and other entities"

non-derivative financial

"the common stock transaction is classified as non-derivative"

Revocable Trust financial

"1,242 shares are held by the Young-Plaisance Revocable Trust"

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Processa Pharmaceuticals (PCSA) report for David Young?

Processa Pharmaceuticals reported that David Young executed an open-market purchase of 2,067 common shares on June 15, 2026 at $2.22 per share. This transaction increased his directly held stake in the company.

How many Processa Pharmaceuticals (PCSA) shares does David Young hold directly after the trade?

After buying 2,067 shares at $2.22, David Young directly holds 19,198 shares of Processa Pharmaceuticals common stock. These shares are listed as directly owned, separate from his additional indirect holdings reported in the same filing.

What indirect Processa Pharmaceuticals (PCSA) holdings are associated with David Young?

The filing lists indirect holdings of 1,009 shares through CorLyst, LLC, 432 shares through Family Entities, and 1,242 shares through the Young-Plaisance Revocable Trust. These positions are reported as indirectly owned common stock.

What was the purchase price in David Young’s Processa Pharmaceuticals (PCSA) transaction?

David Young’s open-market purchase of Processa Pharmaceuticals common stock was made at a price of $2.22 per share. The transaction covered 2,067 shares, and the filing classifies it as a non-derivative, open-market purchase.

What is David Young’s role at Processa Pharmaceuticals (PCSA) mentioned in the filing?

David Young is identified as both a director and the President of Research & Development at Processa Pharmaceuticals. His Form 4 filing reflects insider trading activity associated with this executive and board-level position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/16/2026 - 04:24 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young David

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Pres. Research & Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/15/2026		P		2,067	A	$2.22	19,198	D
Common Stock								1,242	I	By Young-Plaisance Revocable Trust
Common Stock								432	I	By Family Entities
Common Stock								1,009	I	By CorLyst, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ David Young by John J. Wolfel, as Attorney-in-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)